Michael Okunewitch
Stock Analyst at Maxim Group
(1.46)
# 3,514
Out of 5,033 analysts
29
Total ratings
28%
Success rate
-0.53%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $3.03 | +230.03% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $1.75 | +242.74% | 3 | Sep 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $2.77 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $3.96 | +783.84% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $6.13 | +95.92% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $3.42 | +718.71% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.55 | +803.23% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.66 | +80.72% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.56 | +157.23% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.41 | +2,806.98% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.83 | +627.27% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.92 | +1,197.44% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.94 | +1,137.11% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.62 | +587.02% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.37 | +85,343.04% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $18.98 | +31.72% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.60 | +275.00% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $6.05 | +313.56% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.68 | +5,852.38% | 1 | Nov 30, 2021 |
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $3.03
Upside: +230.03%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $1.75
Upside: +242.74%
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.77
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $3.96
Upside: +783.84%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $6.13
Upside: +95.92%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $3.42
Upside: +718.71%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.55
Upside: +803.23%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.66
Upside: +80.72%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.56
Upside: +157.23%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.41
Upside: +2,806.98%
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.83
Upside: +627.27%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.92
Upside: +1,197.44%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.94
Upside: +1,137.11%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.62
Upside: +587.02%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.37
Upside: +85,343.04%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $18.98
Upside: +31.72%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.60
Upside: +275.00%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $6.05
Upside: +313.56%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.68
Upside: +5,852.38%